SAN FRANCISCO — Just weeks after the FDA demanded it stop marketing its take-home genetic tests, 23andMe Inc. now faces two consumer class actions, accusing it of marketing a dangerous product in violation of federal safety rules.
Until it received a “warning letter” from the U.S. Food and Drug Administration late last month, the genetic test maker had sold its DNA Saliva Collection Kit for $99, promising customers who mail back a sample of their saliva a breakdown of their risk factors for inherited disorders as well as detailed analyses of their ancestry.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
